A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) T-cell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAF_FRontier-1 Trial in Progress)
Krish Patel, Gilles Salles(Memorial Sloan Kettering Cancer Center), Laurie H. Sehn(BC Cancer Agency), Georg Lenz(Charité - Universitätsmedizin Berlin), Hong‐Mei Han(Loxo Oncology at Lilly (United States)), Toby A. Eyre(Oxford University Hospitals NHS Trust), Tycel Phillips(Michigan Medicine), Chan Y. Cheah(The University of Western Australia), Stephen J. Schuster(Hospital of the University of Pennsylvania), Minna Balbas(Roswell Park Comprehensive Cancer Center), Jennifer L. Crombie(Dana-Farber Cancer Institute), Nirav N. Shah(Medical College of Wisconsin), Michael Dickinson(The University of Melbourne), Erica L. Johnston(Eli Lilly (United States)), Ching Ching Leow(Eli Lilly (United States)), Sonya C. Chapman(Eli Lilly (United States)), Donald E. Tsai(University of Pennsylvania)
Cited by 0
Related Papers
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
|New England Journal of Medicine|2010|1.3k